

Made for conjugation

Mobius® ADC Reactor with Single-Use Technology

Making the switch to single-use for conjugation

While there is a general shift toward single-use technologies among mAb manufacturers, the adoption for Antibody Drug Conjugate manufacturing steps is not as common. Facilities are hesitant to adopt single-use methods because they have concerns about compatibility, quality and safety. But sticking with stainless steel or glass manufacturing methods has many limitations.

The limitations of stainless steel or glass manufacturing methods

- Extensive cleaning and sterilization between runs
- Underutilized equipment and costly facility expansions
- Resource intensive methods
- Negative environmental impact
- Difficult to respond quickly to changing demands

The **Mobius® ADC Reactor** allows for flexible manufacturing that reduces risk, is compatible with your existing workflow, and reduces waste for maximum efficiency.




Ultimus® Film

Superior film resistance with Ultimus film

- No drip no splash with reagent dip tubes
- Preserved product quality with gentle mAb addition via side port



Flexible Manufacturing



10 L 100 L 500 L

Linear Scale-up with the Mobius® ADC Reactor
Accommodates varying batch sizes, adapting to ADC development phases, and enables smooth scale-up.



30%

Risk Reduction




95%

Potent Liquid Waste Reduction



70%

Increase in Efficiency



Learn more about the Mobius® ADC Reactor
SigmaAldrich.com/ADC-reactor

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.